Barclays Analysts Give Sanofi (EPA:SAN) a €85.00 Price Target

Share on StockTwits

Barclays set a €85.00 ($98.84) target price on Sanofi (EPA:SAN) in a research note issued to investors on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

A number of other brokerages have also recently issued reports on SAN. Deutsche Bank set a €92.00 ($106.98) target price on Sanofi and gave the stock a buy rating in a research report on Wednesday, December 11th. Credit Suisse Group set a €105.00 ($122.09) target price on Sanofi and gave the stock a buy rating in a research report on Friday, February 7th. UBS Group set a €89.50 ($104.07) target price on Sanofi and gave the stock a buy rating in a research report on Thursday, February 6th. HSBC set a €84.00 ($97.67) target price on Sanofi and gave the stock a neutral rating in a research report on Tuesday, December 17th. Finally, JPMorgan Chase & Co. set a €103.00 ($119.77) target price on Sanofi and gave the stock a buy rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Sanofi currently has a consensus rating of Buy and an average price target of €98.35 ($114.36).

Shares of Sanofi stock opened at €92.24 ($107.26) on Wednesday. The stock has a 50 day moving average price of €90.73 and a two-hundred day moving average price of €83.67. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: How accurate is the Rule of 72?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.